Journal
LEUKEMIA RESEARCH
Volume 33, Issue 3, Pages 490-494Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2008.06.014
Keywords
IDO; AML; Kynurenine; Tryptophan; IFN-gamma
Categories
Funding
- Ligue Nationale Contre le Cancer (Equipe Labellisee)
- Fondation de France
- Association de Recherche sur le Cancer (ARC)
- Cent pour Sang la Vie
- Canceropole Nord-Ouest
- Institut de Recherche sur le Cancer de Lille
Ask authors/readers for more resources
The enzyme indoleamine 2,3-dioxygenase (IDO) converts tryptophan to kynurenine, blocking T-cell activation and inducing immunosuppression. In patients with acute myeloid leukemia (AML), the serum kynurenine/tryptophan ratio (Kyn/Trp) was raised, suggesting a higher IDO activity than in healthy people. Patients with higher Kyn/Trp ratios showed lower survival. IDO activity was also detected in AML cells after exposure to IFN-gamma in vitro, suggesting that the higher Kyn/Trp ratio in serum of AML patients might have resulted from stimulated leukemic blast cells. Thus, in AML, the activity of IDO can be easily monitored, providing a tool for future clinical testing of IDO-blocking drugs. (c) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available